Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EPIRUBICIN HAS MODEST SINGLE-AGENT ACTIVITY IN HEAD AND NECK-CANCER BUT LIMITED ACTIVITY IN METASTATIC MELANOMA AND COLORECTAL-CANCER - PHASE-II STUDIES BY THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP
Autore:
ROSENTHAL MA; GREEN M; WIERNIK P; BORDEN EC; MARSH JC; HALLER DG;
Indirizzi:
NYU,MED CTR,KAPLAN CANC CTR,DIV MED ONCOL,C&D BLDG,ROOM 556,462 1ST AVE NEW YORK NY 10016 NYU,MED CTR,KAPLAN COMPREHENS CANC CTR NEW YORK NY 10016 ALBERT EINSTEIN CANC CTR BRONX NY 00000 UNIV MARYLAND,CTR CANC BALTIMORE MD 21201 YALE UNIV,SCH MED NEW HAVEN CT 00000 UNIV PENN PHILADELPHIA PA 19104
Titolo Testata:
American journal of clinical oncology
fascicolo: 5, volume: 21, anno: 1998,
pagine: 509 - 512
SICI:
0277-3732(1998)21:5<509:EHMSAI>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADVANCED MALIGNANT-MELANOMA; 4'-EPI-DOXORUBICIN; CARCINOMA; TRIAL;
Keywords:
EPIRUBICIN; MELANOMA; COLORECTAL; HEAD AND NECK;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
M.A. Rosenthal et al., "EPIRUBICIN HAS MODEST SINGLE-AGENT ACTIVITY IN HEAD AND NECK-CANCER BUT LIMITED ACTIVITY IN METASTATIC MELANOMA AND COLORECTAL-CANCER - PHASE-II STUDIES BY THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP", American journal of clinical oncology, 21(5), 1998, pp. 509-512

Abstract

Epirubicin (4'-epidoxorubicin), a diastereoisomer of doxorubicin, hasestablished activity in the treatment of many cancer types sensitive to doxorubicin. Its activity in other tumor targets such as melanoma, head and neck cancer, and recurrent colorectal cancer has been less well defined. Three concurrent phase IT studies examined the efficacy and toxicity of epirubicin (90 mg/m(2) given intravenously at 3-week intervals) in the treatment of 71 patients with the aforementioned cancers. Of 66 eligible patients who were assessable for response, one patient (with colorectal cancer) achieved a complete response and three patients (with head and neck cancer) achieved partial responses. The response rate in patients with head and neck cancer was 18% (95% confidence interval, 4-43%). Myelosuppression, alopecia, and nausea were the most frequent toxicities. Two patients died of neutropenic sepsis and grade IV leukopenia occurred in six patients (8%). Grade In toxicities were as follows: leukopenia (17%), anemia (10%), alopecia (8%), fever (1%), thrombocytopenia (1%). Grade I or II cardiac toxicity was noted in four patients at cumulative doses ranging between 375 mg/m(2) to 1,283 mg/m(2). Epirubicin is ineffective as a single agent at this dose and schedule in the treatment of patients with melanoma and colorectal cancer. In head and neck cancer, a modest response rate encourages further exploration of epirubicin and related anthracyclines in combination regimens.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 17:11:16